1例胰岛素过敏合并胰岛素自身抗体阳性的暴发性1型糖尿病患者的药学监护

doi:10.19803/j.1672-8629.20210758

中国药物警戒 ›› 2022, Vol. 19 ›› Issue (12): 1376-1379.
DOI: 10.19803/j.1672-8629.20210758

1例胰岛素过敏合并胰岛素自身抗体阳性的暴发性1型糖尿病患者的药学监护

唐彦¹, 王嘉麟², 周婧雅^3,4, 赵维纲⁵, 杜博冉⁶, 胡丹丹⁷, 杨丽萍⁸, 杨莹莹⁹, 赵喆^1,10, 袁涛^5,*

¹中国医学科学院北京协和医学院,北京协和医院药剂科,北京 100010;
²吉林市人民医院药学部,吉林吉林 132001;
³中国医学科学院北京协和医学院病案科,北京 100730;
⁴世界卫生组织疾病分类家族中国合作中心,北京 100730;
⁵中国医学科学院北京协和医学院内分泌科,国家卫生健康委员会内分泌重点实验室,北京 100730;
⁶首都医科大学附属北京妇产医院药事部,北京 100026;
⁷东部战区空军医院药剂科,江苏南京 210002;
⁸邯郸市第一医院药学部,河北邯郸 056000;
⁹成都大学附属医院药剂科,四川成都 610016;
¹⁰中国医学科学院北京协和医学院药物研究所,北京 100050

收稿日期:2021-08-05 出版日期:2022-12-15 发布日期:2022-12-21
通讯作者: ^*袁涛,女,博士,主任医师,糖尿病的基础及临床研究。E-mail：t75y@sina.com
作者简介:唐彦,女,本科,副主任药师,医院药学。
基金资助:
国家科技重大专项重大新药创制（2019ZX09734001）

Pharmaceutical care for a case of fulminant type 1 diabetes with insulin allergy and positive insulin autoantibodies

TANG Yan¹, WANG Jialin², ZHOU Jingya^3,4, ZHAO Weigang⁵, DU Boran⁶, HU Dandan⁷, YANG Liping⁸, YANG Yingying⁹, ZHAO Zhe^1,10, YUAN Tao^5,*

¹Department of Pharmacy, Peking Union Hospital, Chinese Academy of Medical Sciences, Beijing 100010, China;
²Department of Pharmacy, Jilin People’s Hospital, Jilin Jilin 132001, China;
³Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China;
⁴WHO 1Collaborating Center on Family Classification of Diseases, Beijing 100730, China;
⁵Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China;
⁶Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China;
⁷Department of Pharmacy, Air Force Hospital of Easter Theater Command, Nanjing Jiangsu 210002, China;
⁸Department of Pharmacy, Handan First Hospital, Handan Hebei 056000, China;
⁹Department of Pharmacy, Affiliated Hospital of Chengdu University, Chengdu Sichuan 610016, China;
¹⁰Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China

Received:2021-08-05 Online:2022-12-15 Published:2022-12-21

摘要/Abstract

摘要： 目的探讨1例胰岛素过敏合并胰岛素自身抗体阳性的暴发性1型糖尿病患者的用药调整与实施药学监护的方案。方法临床药师参与整个治疗过程,查阅相关文献,根据患者血糖波动特点提出相应建议。结果医师和患者认可临床药师的建议与药学监护,患者血糖控制平稳。结论临床药师运用药学知识,协助医师共同制定治疗方案,对患者进行药学监护,保障了患者合理用药安全。

关键词: 胰岛素过敏, 胰岛素自身抗体, 暴发性1型糖尿病, 药学监护

Abstract: Objective To investigate the importance of medication adjustment and pharmaceutical care for a case of fulminant type 1 diabetes with insulin allergy and positive insulin autoantibodies. Methods Clinical pharmacists participated in the whole process of treatment, reviewed the related literature and offered recommendations according to the fluctuations of the patient’s blood glucose. Results The physicians and patient took the advice of the clinical pharmacists. The blood glucose of the patient was brought under control. Conclusion By using the intimate knowledge of pharmacy, clinical pharmacists can assist physicians in establishing the therapeutic regimen and performing pharmaceutical monitoring of the patient, which can help ensure rational drug use.

Key words: insulin allergy, insulin autoantibody, fulminant type 1 diabetes, pharmaceutical care

中图分类号:

唐彦, 王嘉麟, 周婧雅, 赵维纲, 杜博冉, 胡丹丹, 杨丽萍, 杨莹莹, 赵喆, 袁涛. 1例胰岛素过敏合并胰岛素自身抗体阳性的暴发性1型糖尿病患者的药学监护[J]. 中国药物警戒, 2022, 19(12): 1376-1379.

TANG Yan, WANG Jialin, ZHOU Jingya, ZHAO Weigang, DU Boran, HU Dandan, YANG Liping, YANG Yingying, ZHAO Zhe, YUAN Tao. Pharmaceutical care for a case of fulminant type 1 diabetes with insulin allergy and positive insulin autoantibodies[J]. Chinese Journal of Pharmacovigilance, 2022, 19(12): 1376-1379.

参考文献

[1] ZHOU ZG.Guidelines for diagnosis and treatment of type 1 diabetes in China[M]. Beijing:People’s Medical Publishing House(人民卫生出版社), 2012.
[2] FU J, SHI BY.Fulminant type 1 diabetes: A distinct subtype of type 1 diabetes mellitus[J]. J Formos Med Assoc, 2013, 112(6): 363-364.
[3] WANG O, PAN H, XIANG HD.A case of human insulin allergy[J]. Chinese Journal of Diabetes(中国糖尿病杂志), 2002, 10(5): 306-307.
[4] CHAKRABORTY PP, BISWAS SN, PATRA S.Faulty injection technique: a preventable but often overlooked factor in insulin allergy[J]. Diabetes Ther, 2016, 7(1): 163-167.
[5] JIN RC, HUANG J.Clinical characteristics and management of allergic reaction to insulin preparation[J]. Chinese Journal of Endocrinology and Metabolis(中华内分泌代谢杂志), 2013, 29(9): 1-4.
[6] WATANABE K, KUSUNOKI Y, KATSUNO T, et al.A case of type 1 diabetes mellitus with which localized insulin allergy was markedly alleviated by switching to insulin glulisine[J]. Acta Diabetol, 2016, 53(5): 845-848.
[7] BECKER RH, FRICK AD.Clinical pharmacokinetics and pharmacodynamics of insulin glulisine[J]. Clin Pharmacokinet, 2008, 47(1): 7-20.
[8] GARG SK, ELLIS SL, ULRICH H.Insulin glulisine: a new rapid-acting insulin analogue for the treatment of diabetes[J]. Expert Opin Pharmacother, 2005, 6(4): 643-651.
[9] WATANABE K, KUSUNOKI Y, KATSUNO T, et al.A case of type 1 diabetes mellitus with which localized insulin allergy was markedly alleviated by switching to insulin glulisine[J]. Acta Diabetol, 2016, 53(5): 845-848.
[10] ZHAO WG.Selection of fast insulin analogues in insulin pump therapy based on guidelines[J]. Drug Evaluation(药品评价), 2020, 17(9):1-3, 29.
[11] HOOGMA RP, SCHUMICKI D.Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes[J]. Horm Metab Res, 2006, 38(6): 429-433.
[12] MUNIR KM, DAVIS SN.The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus[J]. Expert Opin Pharmacother, 2015, 16(15): 2331-2341.
[13] TATTERSALL R.Alpha-glucosidase inhibition as an adjunct to the treatment of type 1 diabetes[J]. Diabet Med, 1993, 10(8): 688-693.
[14] DIMITRIADIS GD, TESSARI P, GO VL, et al.alpha-Glucosidase inhibition improves postprandial hyperglycemia and decreases insulin requirements in insulin-dependent diabetes mellitus[J]. Metabolism, 1985, 34(3): 261-265.
[15] YUKINA M, NURALIEVA N, SOLOVYEV M, et al.Insulin autoimmune syndrome[J]. Endocrinol Diabetes Metab Case Rep, 2020 Jun 4, 2020: 190159.
[16] OAK S, PHAN TH, GILLIAM LK, et al.Animal insulin therapy induces a biased insulin antibody response that persists for years after introduction of human insulin[J]. Acta Diabetol, 2010, 47(2):131-135.
[17] ISHIZUKA T, OGAWA S, MORI T, et al.Characteristics of the antibodies of two patients who developed daytime hyperglycemia and morning hypoglycemia because of insulin antibodies[J]. Diabetes Res Clin Pract, 2009, 84(2):e21-e23.
[18] VAN HAEFTEN TW.Clinical significance of insulin antibodies in insulin-treated diabetic patients[J]. Diabetes Care, 1989, 12(9): 641-648.
[19] IONESCU-TÎRGOVIŞTE C, MINCU I, SIMIONESCU L, et al. Disappearance rate of insulin antibodies after discontinuing insulin treatment in 42 type 2 (non-insulin-dependent) diabetic patients[J]. Diabetologia, 1984, 27(6):592-595.
[20] SHEN Y, SONG X, REN Y.Insulin autoimmune syndrome induced by exogenous insulin injection: a four-case series[J]. BMC Endocr Disord, 2019, 19(1): 148.
[21] QUAN H, TAN H, LI Q, et al.Immunological hypoglycemia associated with insulin antibodies induced by exogenous insulin in 11 Chinese patients with diabetes[J]. J Diabetes Res, 2015, 2015: 1-9.
[22] BODE BW.Comparison of pharmacokinetic properties, physicochemical stability, and pump compatibility of 3 rapid-acting insulin analogues-aspart, lispro, and glulisine[J]. Endocr Pract, 2011, 17(2): 271-280.

1例胰岛素过敏合并胰岛素自身抗体阳性的暴发性1型糖尿病患者的药学监护

Pharmaceutical care for a case of fulminant type 1 diabetes with insulin allergy and positive insulin autoantibodies

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	张夏兰, 袁静, 吴斌, 秦媛媛. 甲磺酸阿帕替尼在恶性肿瘤患者的用药特征分析[J]. 中国药物警戒, 2023, 20(8): 927-932.
[2]	王然, 李轶凡, 刘小艳, 冯欣. 1例妊娠期药物暴露风险的药学监护[J]. 中国药物警戒, 2023, 20(8): 933-934.
[3]	刘婧, 夏亮, 张世杰. 1例多元药物过敏急性胰腺炎患者行药物激发试验的药学监护[J]. 中国药物警戒, 2023, 20(7): 822-824.
[4]	杨岩, 周德喜, 吴欣俐, 薛淑雅, 丁海华, 张泉, 张云玲. 84例新型抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2023, 20(3): 334-338.
[5]	姚鑫, 葛秋格, 李亚敏, 王一帆, 李媛媛, 刘志强. 2018~2022年某院新型抗肿瘤药物消化系统不良反应分析[J]. 中国药物警戒, 2023, 20(11): 1273-1278.
[6]	郑金凤, 王景红. 1例多药联用致室性心律失常的药学监护[J]. 中国药物警戒, 2023, 20(11): 1279-1281.
[7]	苏甦, 伍诗琪, 张青霞, 闫素英. 1例吲达帕胺致粒细胞缺乏症患者的药学监护[J]. 中国药物警戒, 2023, 20(11): 1282-1285.
[8]	王燕婷, 张媛媛, 陈怡然, 孙捷, 朱宇, 杨荔艳, 吴知桂, 申丽君, 程敏, 李国辉. 1例恶性肿瘤患者抗感染与抗肿瘤治疗的平衡抉择及药学监护[J]. 中国药物警戒, 2023, 20(10): 1168-1172.
[9]	王祺茹, 左丽, 杜琼, 叶玲, 阮聪, 翟青, 徐蕊. 1例奥拉帕利致Ⅳ度骨髓抑制患者的药学监护[J]. 中国药物警戒, 2023, 20(10): 1176-1180.
[10]	孙雪林, 张攀, 胡欣. 1例维得利珠单抗治疗重症溃疡性结肠炎的药学监护[J]. 中国药物警戒, 2022, 19(7): 782-785.
[11]	唐静雅. 临床药师参与1例肠外营养相关性肝损伤治疗的药学监护[J]. 中国药物警戒, 2022, 19(7): 786-788.
[12]	李雁铭, 赵志刚. 基于循证的伊布替尼不良反应及药学监护[J]. 中国药物警戒, 2022, 19(7): 807-811.
[13]	刘蕾, 张会娟, 钱效森, 孙瑞芳. 1例磺胺脱敏方案治疗干燥综合征合并卡氏肺孢子菌肺炎的药学监护[J]. 中国药物警戒, 2022, 19(6): 680-683.
[14]	周鹏, 杨晶晶. 3种清热解毒类中药注射剂的药学监护[J]. 中国药物警戒, 2022, 19(4): 441-445.
[15]	杜婧,李永辉,阎纳新,郭立杰,刘洋. 1例哌拉西林他唑巴坦治疗肺脓肿患者致药物热及横纹肌溶解症药学监护[J]. 中国药物警戒, 2022, 19(4): 450-452.